Quantcast
Roche's tiragolumab receives U.S. breakthrough therapy designation - Metro US

Roche’s tiragolumab receives U.S. breakthrough therapy designation

FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen as the company said problems at a new warehouse delayed the dispatch of some products

ZURICH (Reuters) – Drugmaker Roche’s novel cancer immunotherapy tiragolumab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration in combination with Roche’s Tecentriq in the treatment of non-small cell lung cancer, the Swiss company said on Tuesday.

The designation had been granted based on results of a phase II CITYSCAPE trial, Roche said.

(Reporting by Brenna Hughes Neghaiwi, editing by Silke Koltrowitz)

More from our Sister Sites